NCT04617119 is a NA clinical trial of Threshold IMT device in Covid19, sponsored by DR. JASSIM ALGHAITH.

Who is sponsoring NCT04617119?

NCT04617119 is sponsored by DR. JASSIM ALGHAITH.

What drugs are being tested in NCT04617119?

Interventions in NCT04617119: Threshold IMT device, Conventional physical therapy.

What condition does NCT04617119 study?

NCT04617119 studies Covid19, Severe Systemic Illness Respiratory Muscle Fatigue.

Is NCT04617119 still recruiting?

NCT04617119 is currently status unknown. Last updated 5 November 2020.

Last reviewed 2020-11-05 · How we verify

NCT04617119

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Multi-modality Physiotherapy in Delaying or Preventing COVID-19 Patient From Admitting to ICU

Status unknown NA Last updated 5 November 2020

What this trial tests

NA trial testing Threshold IMT device in Covid19 in 38 participants. Status unknown.

Timeline

1 November 2020

Primary endpoint
6 February 2021

6 April 2021

Quick facts

Lead sponsor	DR. JASSIM ALGHAITH
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	38
Start date	1 November 2020
Primary completion	6 February 2021
Estimated completion	6 April 2021
Sites	1 location across Kuwait

Drugs / interventions tested

Threshold IMT device
Conventional physical therapy

Conditions studied

Covid19 — all drugs for Covid19 →
Severe Systemic Illness Respiratory Muscle Fatigue — all drugs for Severe Systemic Illness Respiratory Muscle Fatigue →

Sponsor

DR. JASSIM ALGHAITH

Who can join

Adults 21 to 60, any sex, with Covid19 or Severe Systemic Illness Respiratory Muscle Fatigue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effectiveness of respiratory muscle training with COVID-19 patient, who has underlying health conditions, in order to delay or prevent them from admitting to ICU.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04617119 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by DR. JASSIM ALGHAITH
Last refreshed: 5 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04617119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing